Perifosine

別名：KRX-0401, NSC639966, D21266

製品コード：S1037 純度：97%

Perifosine is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

CAS No. 157716-52-4

サイズ	価格(税別)	在庫状況
5mg	JPY 22000	国内在庫あり
10mg	JPY 40500	国内在庫あり
25mg	JPY 70500	国内在庫あり

代表番号: 045-509-1970\|電子メール：[email protected] よく尋ねられる質問

文献中Selleckの製品使用例（164）

質量管理及び製品安全説明書

現在のバッチを見る： 純度：>97%

Perifosine関連製品

関連ターゲット	Akt1 Akt2 Akt3	もっと見る
関連製品	MK-2206 2HCl SC79 Capivasertib (AZD5363) GSK690693 Ipatasertib (GDC-0068) Triciribine (API-2) CCT128930 Afuresertib (GSK2110183) A-674563 HCl AT7867 Oridonin Akti-1/2 PHT-427 TIC10 (ONC201) Miransertib (ARQ 092) HCl AT13148 Uprosertib (GSK2141795) Miransertib (ARQ-092) SC66 Deguelin ML-9 HCl	もっと見る
関連化合物ライブラリー	Kinase Inhibitor Library PI3K/Akt Inhibitor Library Apoptosis Compound Library Cell Cycle compound library NF-κB Signaling Compound Library	もっと見る

シグナル伝達経路

Aktシグナル伝達経路

Akt阻害剤の選択性比較

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	活性情報	PMID
NCI-H727	Cell Viability Assay	0-100 μM	24/72 h	decreases cell viability in both dose and time dependent manner	22499437
GOT1	Cell Viability Assay	0-100 μM	24/72 h	decreases cell viability in both dose and time dependent manner	22499437
BON1	Cell Viability Assay	0-100 μM	24/72 h	decreases cell viability in both dose and time dependent manner	22499437
BON1	Apoptosis Asssay	0-10 μM	24 h	induces apoptosis dose dependently	22499437
BON1	Function Assay	7.5/10 μM	8 h	decreases the expression of the anti-apoptotic proteins BCL2 and Bcl-XL	22499437
Kasumi-1	Cell Viability Assay	0-20 μM	24/48 h	decreases cell viability in both dose and time dependent manner	22407228
HL-60	Cell Viability Assay	0-20 μM	24/48 h	decreases cell viability in both dose and time dependent manner	22407228
Kasumi-1	Apoptosis Asssay	10 μM	24 h	induces apoptosis	22407228
HL-60	Apoptosis Asssay	10 μM	24 h	induces apoptosis	22407228
Kasumi-1	Function Assay	2.5/5/10 μM	24 h	decreases Akt and p-Akt levels dose-dependently	22407228
HL-60	Function Assay	2.5/5/10 μM	24 h	decreases Akt and p-Akt levels dose-dependently	22407228
Kasumi-1	Function Assay	2.5/5/10 μM	24 h	induces the phosphorylation of JNK1/2 in a dose dependent manner	22407228
HL-60	Function Assay	2.5/5/10 μM	24 h	induces the phosphorylation of JNK1/2 in a dose dependent manner	22407228
K562	Function Assay	20 μM	48 h	induces autophagy	22407228
OCUT1	Growth Inhibition Assay	0.1-3 μM	5 d	inhibits cell growth in a dose dependent manner	22090271
K1	Growth Inhibition Assay	0.1-3 μM	5 d	inhibits cell growth in a dose dependent manner	22090271
OCUT1	Function Assay	3 μm	24 h	causes a dramatic increase in G2/M phase	22090271
CaOV3	Cell Viability Assay	1/5/10 μM	48 h	decreases cell viability in a dose dependent manner cotreated with paclitaxel	21775054
SKOV3	Cytotoxicity Assay	5 μM	48 h	enhances paclitaxel induced ovarian cancer cell death	21775054
A2780	Cytotoxicity Assay	5 μM	48 h	enhances paclitaxel induced ovarian cancer cell death	21775054
HT-29	Cytotoxicity Assay	5 μM	48 h	enhances paclitaxel induced ovarian cancer cell death	21775054
A498	Growth Inhibition Assay	0-40 μM	72 h	inhibits cell growth in a dose dependent manner	21644050
CAKI-1	Growth Inhibition Assay	0-40 μM	72 h	IC50~10 μM	21644050
769-P	Growth Inhibition Assay	0-40 μM	72 h	IC50~5-10 μM	21644050
786-0	Growth Inhibition Assay	0-40 μM	72 h	IC50~5 μM	21644050
786-O	Growth Inhibition Assay	0-20 μM	72 h	inhibits cell growth in a dose dependent manner	21644050
CAKI-1	Growth Inhibition Assay	0-20 μM	72 h	inhibits cell growth in a dose dependent manner	21644050
769-P	Growth Inhibition Assay	0-20 μM	72 h	inhibits cell growth in a dose dependent manner	21644050
A498	Growth Inhibition Assay	0-20 μM	72 h	inhibits cell growth in a dose dependent manner	21644050
CWR22RV1	Cell Viability Assay	10 μM	24 h	increases sensitivity of human CWR22RV1 cells to radiation	21496273
CWR22RV1	Apoptosis Asssay	10 μM	24 h	enhances radiation induced apoptosis	21496273
CWR22RV1	Function Assay	5 μM	24 h	reduced phosphorylation of Akt significantly	21496273
HepG2	Growth Inhibition Assay	5/10/20/40 μM	24/48/72 h	inhibits cell growth in both time and dose dependent manner	20842425
Bel-7402	Growth Inhibition Assay	5/10/20/40 μM	24/48/72 h	inhibits cell growth in both time and dose dependent manner	20842425
HepG2	Function Assay	5/10/20 μM	24 h	results in the accumulation of cell number in the G2/M phase	20842425
Bel-7402	Function Assay	5/10/20 μM	24 h	results in the accumulation of cell number in the G2/M phase	20842425
HepG2	Apoptosis Asssay	5/10/20 μM	24/48 h	induces apoptosis at the long-time exposure	20842425
Bel-7402	Apoptosis Asssay	5/10/20 μM	24/48 h	induces apoptosis at the long-time exposure	20842425
OAW-42	Growth Inhibition Assay	0-40 μM	72 h	IC50~10 μM, inhibits cell growth in a dose dependent manner	20405296
PA-1	Growth Inhibition Assay	0-40 μM	72 h	IC50~25 μM, inhibits cell growth in a dose dependent manner	20405296
SKOV3	Growth Inhibition Assay	0-40 μM	72 h	IC50~30 μM, inhibits cell growth in a dose dependent manner	20405296
A2780	Growth Inhibition Assay	0-20 μM	48/72 h	IC50 = 3 μm	20405296
A2780cis	Growth Inhibition Assay	0-20 μM	48/72 h	IC50 = 6 μm	20405296
SKW6.4	Growth Inhibition Assay	2-10 μM	48 h	inhibits cell growth in a dose dependent manner	20130960
MAVER	Growth Inhibition Assay	2-10 μM	48 h	inhibits cell growth in a dose dependent manner	20130960
BJAB	Growth Inhibition Assay	2-10 μM	48 h	inhibits cell growth in a dose dependent manner	20130960
OCI	Growth Inhibition Assay	2-10 μM	48 h	inhibits cell growth in a dose dependent manner	20130960
MOLM	Growth Inhibition Assay	2-10 μM	48 h	inhibits cell growth in a dose dependent manner	20130960
HL-60	Growth Inhibition Assay	2-10 μM	48 h	inhibits cell growth in a dose dependent manner	20130960
SKW6.4	Apoptosis Asssay	10 μM	24/48 h	induces apoptosis time-dependently	20130960
MAVER	Apoptosis Asssay	10 μM	24/48 h	induces apoptosis time-dependently	20130960
BJAB	Apoptosis Asssay	10 μM	24/48 h	induces apoptosis time-dependently	20130960
OCI	Apoptosis Asssay	10 μM	24/48 h	induces apoptosis time-dependently	20130960
MOLM	Apoptosis Asssay	10 μM	24/48 h	induces apoptosis time-dependently	20130960
HL-60	Apoptosis Asssay	10 μM	24/48 h	induces apoptosis time-dependently	20130960
MGC803	Function Assay	0.75/10 μM	48 h	decreases p-Akt (Ser 473), p-GSK3β (Ser 9), and C-MYC levels	23912246
SGC7901	Function Assay	0.75/10 μM	48 h	decreases p-Akt (Ser 473), p-GSK3β (Ser 9), and C-MYC levels	23912246
U87MG	Cell Viability Assay	0-25 μM	24-96 h	decreases cell viability in both dose and time dependent manner	24065522
AsPC-1	Function Assay	0.5 μM	24 h	inhibits Akt, S6K1, and Erk1/2 phosphorylation	24519751
MIA	Function Assay	0.5 μM	24 h	inhibits Akt, S6K1, and Erk1/2 phosphorylation	24519751
PANC-1	Function Assay	0.5 μM	24 h	inhibits Akt, S6K1, and Erk1/2 phosphorylation	24519751
AsPC-1	Growth Inhibition Assay	0-25 μM	72 h	inhibits cell growth in a dose dependent manner	24519751
MIA	Growth Inhibition Assay	0-25 μM	72 h	inhibits cell growth in a dose dependent manner	24519751
PANC-1	Growth Inhibition Assay	0-25 μM	72 h	inhibits cell growth in a dose dependent manner	24519751
Ema	Growth Inhibition Assay	0.1–100 μM	48 h	IC50=58.7 μM	24881508
UL-1	Growth Inhibition Assay	0.1–100 μM	48 h	IC50=7.01 μM	24881508
CLBL-1	Growth Inhibition Assay	0.1–100 μM	48 h	IC50=33.0 μM	24881508
GL-1	Growth Inhibition Assay	0.1–100 μM	48 h	IC50=9.91 μM	24881508
MDA-MB-231	Growth Inhibition Assay	0-10 μM	48 h	EC50=1.13 ± 0.07 μM	25293576
HCC1806	Growth Inhibition Assay	0-10 μM	48 h	EC50=2.84 ± 0.07 μM	25293576
RMG2	Apoptosis Asssay	30 μM	24 h	induces apoptosis	25519148
RMG1	Apoptosis Asssay	30 μM	24 h	induces apoptosis	25519148
A2780	Cell Viability Assay	1-30 μM	48 h	decreases cell viability in a dose dependent manner	25519148
SKOV3	Cell Viability Assay	1-30 μM	48 h	decreases cell viability in a dose dependent manner	25519148
OVISE	Cell Viability Assay	1-30 μM	48 h	decreases cell viability in a dose dependent manner	25519148
RMG2	Cell Viability Assay	1-30 μM	48 h	decreases cell viability in a dose dependent manner	25519148
HAC2	Cell Viability Assay	1-30 μM	72 h	decreases cell viability in a dose dependent manner	25519148
KOC7C	Cell Viability Assay	1-30 μM	72 h	decreases cell viability in a dose dependent manner	25519148
RMG2	Cell Viability Assay	1-30 μM	72 h	decreases cell viability in a dose dependent manner	25519148
RMG1	Cell Viability Assay	1-30 μM	72 h	decreases cell viability in a dose dependent manner	25519148
H460	Function Assay	3 μM	8 h	blocks mTORC1, and ERK-MAPK activation combined with MEK-162	25697899
A549	Function Assay	3 μM	8 h	blocks mTORC1, and ERK-MAPK activation combined with MEK-162	25697899
H460	Function Assay	3 μM	8 h	blocks AKT activation	25697899
A549	Function Assay	3 μM	8 h	blocks AKT activation	25697899
H460	Apoptosis Asssay	1/3 μM	48 h	induces apoptosis	25697899
A549	Apoptosis Asssay	1/3 μM	48 h	induces apoptosis	25697899
H460	Growth Inhibition Assay	0.3-10 μM	24/72 h	inhibits cell growth in both time and dose dependent manner	25697899
A549	Growth Inhibition Assay	0.3-10 μM	24/72 h	inhibits cell growth in both time and dose dependent manner	25697899
U-87 MG	Growth Inhibition Assay	20/40 μM	24/48 h	inhibits cell growth in both time and dose dependent manner	25934232
HepG2	Growth Inhibition Assay	20/40 μM	24/48 h	inhibits cell growth in both time and dose dependent manner	25934232
U-87 MG	Function Assay	20 μM	6/24 h	increases the autophagic flux at 6 h while inhibits this flux at 24h	25934232
HepG2	Function Assay	20 μM	6/24 h	decreases LC3-II degradation from 6 h	25934232
U-87 MG	Function Assay	20 μM	6/24 h	increases the levels of LC3-II cotreated with CQ	25934232
HepG2	Function Assay	20 μM	6/24 h	increases the levels of LC3-II cotreated with CQ	25934232
U-87 MG	Function Assay	20 μM	24 h	increases double-membrane bound structures	25934232
HepG2	Function Assay	20 μM	24 h	produces an intense cytoplasmic vacuolization corresponding to a notable dilatation of the ER cisterns	25934232
T24 BC	Apoptosis Asssay	2.5 μM	24 h	sensitizes BC cells to sorafenib-induced apoptotic	26097873
T24 BC	Cell Viability Assay	0.5/1/2.5 μM	24 h	enhances sorafenib-induced cell viability decrease	26097873
T24 BC	Function Assay	0.5/1/2.5 μM	3 h	reduces the basal CB tyrosine phosphorylation levels in a dose-dependent manner	26097873
A549	Function assay		30 mins	Inhibition of Akt phosphorylation in insulin-stimulated human A549 cells treated 2 hrs before insulin stimulation measured after 30 mins by ELISA, IC50=5.3μM	22138309
A549	Cytotoxicity assay		24 hrs	Cytotoxicity against human A549 cells after 24 hrs by FACS analysis, IC50=7μM	22138309
KATO III	Cytotoxicity assay		24 hrs	Cytotoxicity against human KATO III cells after 24 hrs by FACS analysis, IC50=12.8μM	22138309
MCF7	Cytotoxicity assay		24 hrs	Cytotoxicity against human MCF7 cells after 24 hrs by FACS analysis, IC50=13.3μM	22138309
A549	Function assay		2 hrs	Inhibition of Akt phosphorylation in human insulin-stimulated A549 cells incubated for 2 hrs prior to insulin-induction measured after 30 mins by ELISA, IC50=5.3μM	23415083
PC3	Growth inhibition assay		48 hrs	Growth inhibition of human PC3 cells after 48 hrs by SRB assay, GI50=0.44μM	24095759
NUGC3	Growth inhibition assay		48 hrs	Growth inhibition of human NUGC3 cells after 48 hrs by SRB assay, GI50=0.54μM	24095759
HCT15	Growth inhibition assay		48 hrs	Growth inhibition of human HCT15 cells after 48 hrs by SRB assay, GI50=1.25μM	24095759
MDA-MB-231	Growth inhibition assay		48 hrs	Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay, GI50=2.86μM	24095759
NCI-H23	Growth inhibition assay		48 hrs	Growth inhibition of human NCI-H23 cells after 48 hrs by SRB assay, GI50=4.21μM	24095759
ACHN	Growth inhibition assay		48 hrs	Growth inhibition of human ACHN cells after 48 hrs by SRB assay, GI50=4.56μM	24095759
A549	Cytotoxicity assay		24 to 72 hrs	Cytotoxicity against human A549 cells after 24 to 72 hrs by haemocytometry, IC50=4.17μM	24900620
OVCAR8	Growth Inhibition Assay			IC50=31.1 μM	23877012
HeyA8	Growth Inhibition Assay			IC50=24.3 μM	23877012
A2780CP	Growth Inhibition Assay			IC50=7.6 μM	23877012
OVCAR5	Growth Inhibition Assay			IC50=6.7 μM	23877012
A2780S	Growth Inhibition Assay			IC50=14.5 μM	23877012
MCAS	Growth Inhibition Assay			IC50=12.5 μM	23877012
M41R	Growth Inhibition Assay			IC50=19.8 μM	23877012
M41	Growth Inhibition Assay			IC50=24.7 μM	23877012
TykNuR	Growth Inhibition Assay			IC50=5.5 μM	23877012
TykNu	Growth Inhibition Assay			IC50=3.5 μM	23877012
RBL2H3	Function assay			Toxicity in rat RBL2H3 cells, MTD=25μM	20153565
PC3	Growth inhibition assay			Growth inhibition of human PC3 cells by sulforhodamine B assay, GI50=0.44μM	21543141
NUGC3	Growth inhibition assay			Growth inhibition of human NUGC3 cells by sulforhodamine B assay, GI50=0.54μM	21543141
HCT15	Growth inhibition assay			Growth inhibition of human HCT15 cells by sulforhodamine B assay, GI50=1.25μM	21543141
MDA-MB-231	Growth inhibition assay			Growth inhibition of human MDA-MB-231 cells by sulforhodamine B assay, GI50=2.86μM	21543141
NCI-H23	Growth inhibition assay			Growth inhibition of human NCI-H23 cells by sulforhodamine B assay, GI50=4.21μM	21543141
ACHN	Growth inhibition assay			Growth inhibition of human ACHN cells by sulforhodamine B assay, GI50=4.56μM	21543141
PC3	Growth inhibition assay			Growth inhibition of human PC3 cells by SRB assay, GI50=0.44μM	23266181
NUGC3	Growth inhibition assay			Growth inhibition of human NUGC3 cells by SRB assay, GI50=0.54μM	23266181
HCT15	Growth inhibition assay			Growth inhibition of human HCT15 cells by SRB assay, GI50=1.25μM	23266181
MDA-MB-231	Growth inhibition assay			Growth inhibition of human MDA-MB-231 cells by SRB assay, GI50=2.86μM	23266181
NCI-H23	Growth inhibition assay			Growth inhibition of human NCI-H23 cells by SRB assay, GI50=4.21μM	23266181
ACHN	Growth inhibition assay			Growth inhibition of human ACHN cells by SRB assay, GI50=4.56μM	23266181
A549	Cytotoxicity assay			Cytotoxicity against human A549 cells by flow cytometric analysis, IC50=7μM	23415083
KATO III	Cytotoxicity assay			Cytotoxicity against human KATO III cells by flow cytometric analysis, IC50=12.8μM	23415083
MCF7	Cytotoxicity assay			Cytotoxicity against human MCF7 cells by flow cytometric analysis, IC50=13.3μM	23415083
PC3	Antiproliferative assay			Antiproliferative activity against human PC3 cells by SRB assay, GI50=0.44μM	23567950
NUGC3	Antiproliferative assay			Antiproliferative activity against human NUGC3 cells by SRB assay, GI50=0.54μM	23567950
HCT15	Antiproliferative assay			Antiproliferative activity against human HCT15 cells by SRB assay, GI50=1.25μM	23567950
MDA-MB-231	Antiproliferative assay			Antiproliferative activity against human MDA-MB-231 cells by SRB assay, GI50=2.86μM	23567950
NCI-H23	Antiproliferative assay			Antiproliferative activity against human NCI-H23 cells by SRB assay, GI50=4.21μM	23567950
ACHN	Antiproliferative assay			Antiproliferative activity against human ACHN cells by SRB assay, GI50=4.56μM	23567950
Rosetta cells	Function assay			Inhibition of wild-type human P38alpha MAPK expressed in Escherichia coli Rosetta cells, IC50=1.2μM	31274316
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明

Perifosine is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

Targets

Akt ^[1]
(MM.1S cells)

4.7 μM

In Vitro
In vitro	Perifosine develops anti-proliferative properties with IC50 of 0.6-8.9 μM in immortalized keratinocytes (HaCaT), and head and neck squamous carcinoma cells. ^[1] Perifosine strongly reduces phosphorylation levels of Akt and extracellular signal-regulated kinase (Erk) 1/2, induces cell cycle arrest in G1 and G2, and causes dose-dependent growth inhibition of mouse glial progenitors. ^[2] Perifosine (10 μM) completely inhibits the phosphorylation of Akt in MM.1S cells. ^[3] A recent study demonstrates Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. ^[4]
Kinase Assay	Akt kinase assay
Kinase Assay	MM.1S cells are cultured in the presence or absence of perifosine (5 μM, 6 hours) and then stimulated with IL-6 (20 ng/mL, 10 minutes). In vitro akt kinase assay is then carried out using the Akt Kinase Assay Kit.
細胞実験	細胞株	Human glioma cell lines
	濃度	0, 15, 30 and 45 μM
	反応時間	48 hours
	実験の流れ	Cells are incubated in the medium with 10% FCS for 48 hours with indicated concentration of Periosine. Cell viability is determined by the MTT assay. (Cell Proliferation Kit I; Roche). The absorbance at 590 nm is recorded using the 96-well plate reader.
実験結果図	Methods	Biomarkers	結果図	PMID
	Western blot	p-AKT / AKT / p-S6K1 / S6K1 PARP p-mTOR / mTOR / Raptor / Rictor / p-p70S6K / p70S6K / p-4EBP1 / 4EBP1 / c-Myc / Cyclin D1 p-PDK1 / p-GSK3α/β / p-S6R		25519148
	Growth inhibition assay	Cell viability		28332584

In Vivo
In Vivo	Perifosine in combination reduces tumor proliferation (a PDGF-driven gliomagenesis) in vivo. The results indicate that Perifosine is an effective drug in gliomas in which Akt and Ras-Erk 1/2 pathways are frequently activated, and may be new candidate for glima treatment in the clinic. ^[2] Both oral daily and weekly administration of Perifosine significantly reduce human MM tumor growth and increase survival, compared with control animals treated with PBS vehicle only. ^[3] Perifosine induces thrombocytosis and leukocytosis and increases myelopoiesis in murine marrow and spleen, whereas it causes apoptosis in myeloma xenografts. ^[5]
動物実験	動物モデル	MM.1S MM cells are inoculated subcutaneously in the right flank of Beige-nude-xid (BNX) mice (5 to 6 weeks old).
	投与量	250 mg/kg/wk or 36 mg/kg/d
	投与経路	Oral gavage

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試験 (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT01224730	Completed	Cancer	AEterna Zentaris	January 24 2012	Phase 1
NCT01049841	Completed	Pediatric Solid Tumors	Memorial Sloan Kettering Cancer Center\|University of Wisconsin Madison\|Duke University\|NATL COMP CA NETWORK\|Pfizer\|AEterna Zentaris	January 2010	Phase 1
NCT01048580	Completed	Colon Cancer	AEterna Zentaris\|SCRI Development Innovations LLC	October 2009	Phase 1
NCT00776867	Completed	Solid Tumors	Memorial Sloan Kettering Cancer Center\|University of Wisconsin Madison\|Duke University\|AEterna Zentaris	October 2008	Phase 1

参考
[1] Vyomesh Patel, et al. Cancer Res, 2002, 62(5), 1401-1409 [2] Momota H, et al. Cancer Res, 2005, 65(16), 7429-7435. [3] Hideshima T, et al. Blood, 2006, 107(10), 4053-4062. [4] Fei HR, et al. Cytotechnology, 2010, 62(5), 449-460 [5] Catley L, et al. Exp Hematol, 2007, 32(7), 1038-1046 + 展開

参考

+ 展開

化学情報

分子量	461.66	化学式	C₂₅H₅₂NO₄P
CAS No.	157716-52-4	SDF	Download Perifosine SDFをダウンロードする
Smiles	CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](CC1)(C)C
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1年-80°Cin solvent
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	１ケ月-20°Cin solvent

In vitro
Batch:

Water : 92 mg/mL

Ethanol : 92 mg/mL

DMSO : Insoluble ( 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):